The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Targeting The Anti-angiogenic Factors Of Preeclampsia: Soluble Endoglin And SFlt1
Funder
National Health and Medical Research Council
Funding Amount
$447,024.00
Summary
Preeclampsia is a severe disease of pregnancy - the placenta releases toxins in to mum's bloodstream that circulate her body and damage her organs. As there are no efficacious treatments, clinicians are forced to deliver babies irrespective of gestation. Although the two toxins of preeclampsia have been identified, little is known about their regulation. This project aims to elucidate the regulation of these toxins and design therapeutics that can prevent their release in the clinic.
Soluble Endoglin In The Pathogenesis Of Preeclampsia: Investigation Of Mechanisms And The Development Of Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$572,733.00
Summary
Preeclampsia is a severe disease of pregnancy. As the pathogenesis is poorly understood, the only treatment is for clinicians to deliver babies irrespective of gestation. We have identified MMP-14 as the molecular scissors that release soluble endoglin from placenta, a toxin centrally responsible for severe preeclampsia. In this project we aim to further investigate the mechanisms governing soluble endoglin release and to begin developing a potential therapeutic for use in the clinic.
Nanomedicine Targeted Delivery Of Therapeutics To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$513,148.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in human and mouse models in our laboratory. This work has potential to offer possibilities of new treatments to other pregnancy complications.
Maternal Ophthalmic Artery Doppler Waveform Analysis In The Assessment And Management Of Pre-eclampsia
Funder
National Health and Medical Research Council
Funding Amount
$94,758.00
Summary
Pre-eclampsia is the commonest serious medical problem in pregnancy. Mothers who have this condition are at risk of seizures, stroke and other neurological problems, which can cause death or long-term morbidity. Treatments for pre-eclampsia aim to prevent these problems. Through ultrasound imaging of a blood vessel at the back of the eye, this study will provide new insights into how these treatments change the brain's blood supply in mothers with pre-eclampsia.
Activin Mediated Endothelial Dysfunction: Novel Therapies For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$601,582.00
Summary
Preeclampsia remains a major cause of death of both pregnant women and their babies. The treatment for preeclampsia has not changed in decades. New insights into underlying causes of the disease have offered opportunities for the development of better, more effective treatments. This project aims to test such new therapies in an animal model of the disease with a view to future clinical trials.
Mechanisms Of Impaired Uterine Vascularisation In Early Pregnancy.
Funder
National Health and Medical Research Council
Funding Amount
$570,414.00
Summary
Vascular dysfunction and reduced blood flow to the placenta are underlying causes of pre-eclampsia and hypertension in pregnant women. Our proposal will identify if low circulating levels of the hormone relaxin are causes of abnormal development of the uterine vasculature in early pregnancy. This knowledge will enable us to develop new treatments to improve health outcomes in women at high risk of developing these diseases during their pregnancy.
Sleep-disordered Breathing In Pregnancy-induced Hypertension And Preeclampsia: Maternal And Fetal Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$129,559.00
Summary
Our study aims to compare signs of sleep-disordered breathing (such as snoring and breathing pauses) in pregnant women affected by hypertension or preeclampsia to those with a healthy pregnancy, and to see if they respond differently to the breathing problems. To do this we will examine whether snoring and breathing pauses during sleep have an impact on the pregnant woman’s blood pressure and the unborn baby’s heart rate overnight, and scans will monitor whether the baby’s growth is affected.